Revenue: 955,703 (USD thousands) in QQ2 2025, up 67.08% YoY and down 1.20% QoQ. Gross Profit: 775,052; Gross Margin: 81.10% (vs. 68.15% implied in prior year periods). Operating Income: 145,178; Operating Margin: 15.19% (YoY expansion supported by higher gross margin and contained operating costs). EBITDA: -14,989; EBITDA Margin: -1.57%. Net Income: -38,210; Net Margin: -4.00%. Earnings per Share (EPS): -0.0002. Weighted Avg Shares Outstanding: 229,160,695. Cash from Operations: 39,769; Capital Expenditures: -4,768; Free Cash Flow: 35,001. Cash and Cash Equivalents: 720,014. Total Assets: 1,248,065; Total Liabilities: 1,527,713; Total Shareholders’ Equity: -279,648. Current Ratio: 0.76; Quick Ratio: 0.74; Cash Ratio: 0.47. Days Sales Outstanding (DSO): 31.38; CCC (cash conversion cycle): -46.27 days. Deferred Revenue: 1,336,929; Retained Earnings: -15,522,117. Net Debt: -720,014 (net cash). Revenue mix appears concentrated around ReadyOp/ReadyMed solutions with relatively modest R&D spend (2k-4k per quarter in the data set) and elevated other expenses in the quarter. Key YoY and QoQ drivers suggest improving profitability on an operating basis but ongoing reliance on non-operating items for net income.